E. Patorno

First name
E.
Last name
Patorno
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
Abrahami, D., Tesfaye, H., Yin, H., Vine, S., Hicks, B., H. Y. Yu, O., et al. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021
Suissa, K., Schneeweiss, S., Douros, A., Filion, K. B., Yin, H., Patorno, E., & Azoulay, L. (2021). The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. Diabetes Obes Metab. http://doi.org/10.1111/dom.14494